Clinical trials: Histological Type of Neoplasm
Multiple Myeloma
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in…
- Trial name
- UPFRONT (NCT00507416)
- Testing
- Bortezomib, Dexamethasone, Melphalan
- Where
- 235 sites in United States, Puerto Rico
- Volunteers
- 502 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test
AlloHeme is a chimerism test service that utilizes NGS technology to analyze SNP loci to quantify donor and recipient cells by measuring genomic DNA.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- ACROBAT (NCT04635384)
- Where
- 10 sites in United States
- Volunteers
- 307 people
- Sponsor
- CareDx
Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
Phase III Study to Investigate the Efficacy and Safety of CS1001 or Placebo in Combination with FP as First-Line Therapy in Subjects with Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04187352
- Testing
- CS1001+ Fluorouracil+Cisplatin
- Where
- 72 sites in China
- Volunteers
- 540 people
- Sponsor
- CStone Pharmaceuticals
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or…
- Trial name
- NCT02457793
- Testing
- Cobimetinib, GDC-0994
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Glioblastoma (GBM)
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
The objective of this study is to evaluate the safety, feasibility, and preliminary antitumor activity of this multi-component immunotherapy strategy in patients with advanced solid tumors.
- Trial name
- NCT07762716
- Testing
- BreakVax, Ipilimumab 2.5 mg, Pembrolizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- BreakBio Corp
Relapsed/Refractory Multiple Myeloma
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety and patient-reported outcomes (PROs) associated with standard of care (SOC) antimyeloma treatments in…
- Trial name
- MoMMent (NCT05160584)
- Testing
- No intervention
- Where
- 90 sites in Austria, Belgium and 10 more
- Volunteers
- 300 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Multiple Myeloma
Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics and initial efficacy of AO-176 as monotherapy and in combination with dexamethasone and bortezomib in adults with…
- Trial name
- NCT04445701
- Testing
- AO-176, AO-176 + Dex, AO-176 + Dex + Bort
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Arch Oncology
Melanoma
International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma
An International Multicenter Open-label Randomized Trial of the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) as Monotherapy in Patients with Unresectable/Metastatic Melanoma.
- Trial name
- MIRACULUM (NCT03269565)
- Testing
- BCD-100
- Where
- 9 sites in Russia
- Volunteers
- 126 people
- Sponsor
- Biocad
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
Study of Out of Specification for Tisagenlecleucel
This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of CTL019 in the patients treated within the approved…
- Trial name
- NCT04094311
- Testing
- CTL019
- Where
- 55 sites in Canada, Japan
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia
Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
This is a Phase 1, multicenter, open-label study to evaluate safety, tolerability and pharmacokinetics of milademetan in Japanese patients with relapsed or refractory acute myeloid leukemia.
- Trial name
- NCT03671564
- Testing
- Milademetan
- Where
- 8 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Squamous Cell Carcinoma, Head and Neck Cancer
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the…
- Trial name
- NCT01161498
- Testing
- Talimogene Laherparepvec, Radiation, Cisplatin
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- BioVex Limited
Lymphoma, Non-Hodgkin, HIV Infections
Gene Therapy in HIV-Positive Patients With Non-Hodgkin's Lymphoma
The purpose of this study is to see if it is safe and effective to use gene therapy to treat non-Hodgkin's lymphoma (NHL) in HIV-positive patients. Stem cell transplantation is a procedure used to treat NHL.
- Trial name
- NCT00002221
- Testing
- Peripheral blood stem cells
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ribozyome
Advanced Hematologic Malignancies
Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS)
The purpose of this study is to determine the Maximum Tolerated Dose, Dose Limiting Toxicities and optimal dosing schedule of 4SC-202 investigating its safety, tolerability and pharmacokinetics.
- Trial name
- NCT01344707
- Testing
- 4SC-202
- Where
- 3 sites in Germany
- Volunteers
- 36 people
- Sponsor
- 4SC AG
Chronic Myeloid Leukemia, CML
Study of Olverembatinib (HQP1351) in Patients With CML-CP
Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A).
- Conditions
- Chronic Myeloid Leukemia, CML, CML, Chronic Phase
- Trial name
- POLARIS-2 (NCT06423911)
- Testing
- olverembatinib, Bosutinib
- Where
- 163 sites in United States, Australia and 14 more
- Volunteers
- 333 people
- Sponsor
- Ascentage Pharma Group Inc.
Squamous Cell Carcinoma of Head and Neck
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants…
- Trial name
- OrigAMI-5 (NCT07276399)
- Testing
- Amivantamab, Pembrolizumab, Carboplatin
- Where
- 203 sites in United States, Australia and 20 more
- Volunteers
- 500 people
- Sponsor
- Janssen Research & Development, LLC
Cholangiocarcinoma
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure…
- Trial name
- NCT05874414
- Testing
- GNS561 + Trametinib
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 98 people
- Sponsor
- Genfit
Follicular Lymphoma, Marginal Zone Lymphoma
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an…
- Trial name
- InMIND (NCT04680052)
- Testing
- tafasitamab, rituximab, lenalidomide
- Where
- 261 sites in United States, Australia and 26 more
- Volunteers
- 654 people
- Sponsor
- Incyte Corporation
Leukemia, Myelodysplastic Syndrome(MDS)
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety and efficacy of fadraciclib (formerly CYC065) administered orally BID.
- Trial name
- NCT05168904
- Testing
- fadraciclib
- Where
- 2 sites in United States
- Volunteers
- 210 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Glioblastoma Multiforme
An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse
This single-arm, open-label, multicenter, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in patients with glioblastoma multiforme in first or second relapse.
- Trial name
- NCT01618747
- Where
- 3 sites in Taiwan
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
The purpose of this study is to determine whether AT7519M alone or AT7519M plus bortezomib are effective treatments in patients with previously treated multiple myeloma.
- Trial name
- NCT01183949
- Testing
- AT7519M, Bortezomib
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Astex Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.